Antifungal Resistance Mechanisms

Antifungal resistance mechanisms are the molecular and cellular strategies by which fungi evade the activity of antifungal drugs. Because the major antifungal classes act on a small set of conserved targets - ergosterol and its biosynthesis, the fungal cell-wall glucan synthase, and nucleic-acid synthesis - resistance typically arises by altering those targets, increasing their output, or pumping the drug out of the cell.

Definition

Antifungal resistance mechanisms are the heritable or adaptive changes - including target-enzyme mutation, target overexpression, drug efflux, and biofilm-associated tolerance - that reduce the susceptibility of fungi to antifungal agents.

Scope

This topic explains the principal biochemical and genetic routes to antifungal resistance, organised by drug class, and how they relate to the limited antifungal armamentarium. It is a mechanism-focused microbiology reference. A separately authored node on antifungal resistance mechanisms within the mycology subfield is cross-linked as a neighbour; this entry frames the same mechanisms within the antimicrobial-resistance area.

Core questions

• How does each major antifungal class become subject to resistance?
• Why do target alteration, target overexpression, and efflux recur as themes across drug classes?
• What is the difference between resistance, tolerance, and persistence in fungi?

Key concepts

• ERG11/Cyp51 target mutation and overexpression (azoles)
• Drug efflux pumps (ABC and MFS transporters)
• FKS gene mutations (echinocandins)
• Reduced ergosterol content (polyenes)
• Loss of flucytosine activation or uptake
• Biofilm-associated tolerance
• Cross-resistance and multidrug resistance
• Environmental selection of resistance

Mechanisms

For azoles, resistance arises chiefly through point mutations in and overexpression of ERG11 (encoding the target lanosterol 14-alpha-demethylase, Cyp51), together with upregulation of ABC and MFS efflux transporters that lower intracellular drug levels (Perlin 2017). For echinocandins, resistance is driven by mutations in the FKS1/FKS2 genes encoding the beta-1,3-glucan-synthase target. Polyene resistance is comparatively rare and is associated with reduced or altered ergosterol in the membrane, the polyene-binding sterol. Flucytosine resistance follows loss of the enzymes that take up or activate the drug. Biofilms add a layer of phenotypic tolerance independent of these genetic changes. In Aspergillus fumigatus, characteristic Cyp51A mutations linked to environmental azole exposure illustrate how selection outside the clinic can shape clinical resistance (Verweij 2016; Fisher 2018).

Clinical relevance

Understanding resistance mechanisms underpins susceptibility testing, surveillance, and the interpretation of treatment guidelines, since the mechanism present determines which drug classes remain active (Patterson 2016; Perlin 2017). This entry explains those mechanisms for reference; it does not provide dosing or individualised treatment advice.

Epidemiology

The clinical impact of these mechanisms is most visible in azole-resistant Aspergillus fumigatus and in echinocandin and azole resistance among Candida species, with environmental azole exposure recognised as a driver of resistant mould infection (Fisher 2018; Verweij 2016). The narrow pipeline of antifungal classes makes each resistance mechanism disproportionately consequential (Roemer 2014).

History

As triazoles and later echinocandins entered clinical use, the molecular basis of resistance to each class was progressively defined - target mutations and efflux for azoles, FKS mutations for echinocandins - and the discovery of environmentally selected azole resistance in Aspergillus fumigatus reframed antifungal resistance as a One Health problem (Verweij 2016; Fisher 2018).

Debates

Does environmental azole use select clinically important resistance mechanisms?

Cyp51A-mediated azole resistance in Aspergillus fumigatus has been linked to agricultural azole fungicides, raising debate over how much environmental selection, as opposed to in-host selection during therapy, accounts for clinical resistance.

Key figures

• David S. Perlin
• Paul E. Verweij
• Matthew C. Fisher
• Damian J. Krysan

Seminal works

• perlin-2017
• fisher-2018
• roemer-2014

Frequently asked questions

What is the most common mechanism of azole resistance in fungi?

Resistance to azoles is most commonly due to mutations in and overexpression of the target enzyme ERG11/Cyp51 together with increased drug efflux, which together reduce how effectively the drug inhibits ergosterol synthesis.

How is this node different from the mycology node with a similar name?

A separate node on antifungal resistance mechanisms sits under the mycology subfield; this node covers the same mechanisms but is placed within the antimicrobial-resistance area and is cross-linked to it as a neighbour rather than duplicating it.